16 May Cellular Logistics Seeking New Round of Financing
MADISON, WI, May 16, 2022 – Cellular Logistics, a Madison, Wisconsin company that is creating a new way to restore heart function and help patients with heart damage is launching a new financing round to advance its product, Tandem™, to the next stage of product development, and moving toward human clinical testing.
“We are seeking the right funding partners, those focused on investing in technology that has the potential to replace or regenerate human cells to restore normal function”. For heart failure, this means revitalizing or remuscularizing the damaged heart”, says Alex Vodenlich, President and Chief Executive Officer.
Tandem™, is a novel and patented biomaterial that holds the promise of revitalizing the damaged heart by enabling unique combined therapeutic approaches for the world’s leading cause of death, heart failure. The company’s vision is to help create a path to a new generation of therapies to reverse the debilitating symptoms of heart failure; dramatically reducing re-hospitalization and enabling patients to live longer, healthier lives.
Heart failure affects 6.2 million Americans and is growing faster than predicted. People who are diagnosed, face living with the grave statistic that nearly half of all patients will die within five years of the disease’s onset. This is a worse outcome than in all but a few cancers. Conventional therapies to treat heart failure are inadequate as up to 40% of patients either respond poorly or do not respond at all to these treatments. Re-hospitalization is common leading to a significant financial burden of over $30B annually.
“Clearly new approaches to treat this disease are needed and Tandem™ has the ability to enable these approaches”, says Vodenlich.
About Cellular Logistics
Cellular Logistics, Inc. is dedicated to improving the lives of individuals suffering from cardiovascular disease. CL was founded in 2016 by a multi-disciplinary clinical and scientific team from the University of Wisconsin-Madison School of Medicine and Public Health. Our company vision is to help create a world where a new generation of therapies can reverse the debilitating symptoms of heart failure; dramatically reducing re-hospitalization and enabling patients to live longer, healthier lives.
Press Contact: Alex Vodenlich, firstname.lastname@example.org